Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: RGETNE national NEN Registry comprises 74 hospitals from all regions of Spain.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Garcia Carbonero R, Jimenez-Fonseca P, Benavent M, Alonso V, Crespo G,
Keywords: G3 NEN, epidemiology, survival, patterns of care, response to chemotherapy,
Introduction: RGETNE national NEN Registry comprises 74 hospitals from all regions of Spain.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Garcia Carbonero R, Jimenez-Fonseca P, Benavent M, Alonso V, Alonso T,
Keywords: GEP-NEN, tumor registry, survival, prognosis, epidemiology,
Introduction: Somatostatin analogs (SSAs) are used to treat acromegaly and neuroendocrine tumors (NETs). Two first-generation SSAs, octreotide and lanreotide, are available to patients (pts).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Cella D
Authors: Feuilly M, Jenni E, Cella D,
Keywords: neuroendocrine tumors, acromegaly, preference, patient reported outcomes,
Introduction: Information provided to patients (pts) with neuroendocrine tumors (NETs) about burden and treatment proposed may influence pts’ adherence to treatment, outpatient monitoring and quality of life (QoL), but can also cause anxiety.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Hautefeuille V
Authors: Hautefeuille V, Do Cao C, Coriat R, Dominguez S, Mineur L,
Keywords: Patients’ perception of information, Quality of Life, Lanreotide,
Introduction: Pancreatic neuroendocrine tumors (PNETs) are rare and heterogeneous neoplasms with a 10-year survival rate less than 30%. Up to 43% of them are driven by inactivating mutations in ATRX or DAXX. These are important players at chromatin remodeling, that when mutated prone cancer cells to initiate the alternative lengthening of telomeres (ALT). ALT phenotype correlates with in situ loss of expression of the proteins ATRX or DAXX and can be corroborated by telomere-FISH.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Gaspar T, Pinheiro J, Canberk S, İnce �, Tokat F,
Keywords: pancreas, pancreatic neuroendocrine tumors, PNETs, ATRX, DAXX, ALT, mosaic,